153 related articles for article (PubMed ID: 33794821)
41. Low Papanicolaou smear screening rate of women with HIV infection: a nationwide population-based study in Taiwan, 2000-2010.
Chen YC; Liu HY; Li CY; Lee NY; Ko WC; Chou CY; Hsieh TH; Ko NY
J Womens Health (Larchmt); 2013 Dec; 22(12):1016-22. PubMed ID: 23992102
[TBL] [Abstract][Full Text] [Related]
42. Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change.
Grover S; Bhatia R; Friebel-Klingner TM; Mathoma A; Vuylsteke P; Khan S; Ralefala T; Tawe L; Bazzett-Matabele L; Monare B; Luckett R; Ramogola-Masire D
Cancer Treat Res Commun; 2023; 34():100682. PubMed ID: 36682141
[TBL] [Abstract][Full Text] [Related]
43. Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine.
Bailey H; Thorne C; Semenenko I; Malyuta R; Tereschenko R; Adeyanova I; Kulakovskaya E; Ostrovskaya L; Kvasha L; Cortina-Borja M; Townsend CL
PLoS One; 2012; 7(4):e34706. PubMed ID: 22545087
[TBL] [Abstract][Full Text] [Related]
44. Higher educational attainment associated with reduced likelihood of abnormal cervical lesions among Zambian women - a cross sectional study.
Hamoonga TE; Likwa RN; Musonda P; Michelo C
BMC Cancer; 2017 Oct; 17(1):681. PubMed ID: 29029626
[TBL] [Abstract][Full Text] [Related]
45. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
46. Knowledge, Attitudes, and Practices Regarding Cervical Cancer Screening among HIV-infected Women at Srinagarind Hospital: A Cross-Sectional Study.
Songsiriphan A; Salang L; Somboonpha W; Eamudomkarn N; Nhokaew W; Kuchaisit C; Harnlakorn P
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2979-2986. PubMed ID: 33112557
[TBL] [Abstract][Full Text] [Related]
47. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system.
Chao C; Silverberg MJ; Becerra TA; Corley DA; Jensen CD; Chen Q; Quinn VP
Am J Obstet Gynecol; 2017 Feb; 216(2):151.e1-151.e9. PubMed ID: 27746152
[TBL] [Abstract][Full Text] [Related]
48. Factors associated with advanced-stage diagnosis of cervical cancer in Estonia: a population-based study.
Šavrova A; Jaal J; Nõmm O; Innos K
Public Health; 2023 Dec; 225():369-375. PubMed ID: 37989009
[TBL] [Abstract][Full Text] [Related]
49. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
50. Assessment of mode of delivery and predictors of emergency caesarean section among women living with HIV in a matched-pair setting with women from the general population in Denmark, 2002-2014.
Ørbaek M; Thorsteinsson K; Helleberg M; Moseholm E; Katzenstein TL; Storgaard M; Johansen IS; Pedersen G; Weis N; Lebech AM
HIV Med; 2017 Nov; 18(10):736-747. PubMed ID: 28544321
[TBL] [Abstract][Full Text] [Related]
51. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
52. Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia.
Pärna K; Nygård M; Tisler A; Toompere K; Naaber P; Ratnik K; Ķīvīte Urtāne A; Zodzika J; Stankūnas M; Baltzer N; Uusküla A
BMJ Open; 2023 Jun; 13(6):e069558. PubMed ID: 37263686
[TBL] [Abstract][Full Text] [Related]
53. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
54. Multiple High-Risk HPV Types Contribute to Cervical Dysplasia in Ugandan Women Living With HIV on Antiretroviral Therapy.
Nakisige C; Adams SV; Namirembe C; Okoche L; Ferrenberg J; Towlerton A; Larsen A; Orem J; Casper C; Frenkel L; Uldrick TS
J Acquir Immune Defic Syndr; 2022 Jul; 90(3):333-342. PubMed ID: 35195571
[TBL] [Abstract][Full Text] [Related]
55. Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study.
Pry JM; Manasyan A; Kapambwe S; Taghavi K; Duran-Frigola M; Mwanahamuntu M; Sikazwe I; Matambo J; Mubita J; Lishimpi K; Malama K; Bolton Moore C
Lancet Glob Health; 2021 Jun; 9(6):e832-e840. PubMed ID: 34019837
[TBL] [Abstract][Full Text] [Related]
56. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia.
Veerus P; Arbyn M; Amati C; Paolo B;
Tumori; 2010; 96(4):524-8. PubMed ID: 20968130
[TBL] [Abstract][Full Text] [Related]
57. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
[TBL] [Abstract][Full Text] [Related]
58. Predictors of cervical cancer screening practice among HIV positive women attending adult anti-retroviral treatment clinics in Bishoftu town, Ethiopia: the application of a health belief model.
Solomon K; Tamire M; Kaba M
BMC Cancer; 2019 Oct; 19(1):989. PubMed ID: 31646975
[TBL] [Abstract][Full Text] [Related]
59. Human papillomavirus self-sampling for long-term non-attenders in cervical cancer screening: A randomised feasibility study in Estonia.
Veerus P; Hallik R; Jänes J; Jõers K; Paapsi K; Laidra K; Innos K
J Med Screen; 2022 Mar; 29(1):53-60. PubMed ID: 34694179
[TBL] [Abstract][Full Text] [Related]
60. Unique human papillomavirus-type distribution in South African women with invasive cervical cancer and the effect of human immunodeficiency virus infection.
van Aardt MC; Dreyer G; Pienaar HF; Karlsen F; Hovland S; Richter KL; Becker P
Int J Gynecol Cancer; 2015 Jun; 25(5):919-25. PubMed ID: 25950128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
